Using immune checkpoint inhibitors to manage pain
Targeting checkpoint inhibitors for pain control
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-10771904
This study is looking at how certain proteins in the immune system, called PD-L1 and PD-1, might affect how well pain is managed and how opioids work, using specially modified mice to learn more about pain in different situations.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10771904 on ClinicalTrials.gov |
What this research studies
This research investigates how immune checkpoint proteins, specifically PD-L1 and PD-1, influence pain control and the effectiveness of opioid analgesics. By utilizing genetically modified mice, the study aims to understand the role of these proteins in both normal and pathological pain conditions. The researchers will explore how the PD-L1/PD-1 pathway affects pain signaling in various contexts, including inflammatory and neuropathic pain. This could lead to new therapeutic strategies for pain management by targeting these immune pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from chronic pain conditions, such as neuropathic pain or cancer-related pain.
Not a fit: Patients who do not experience chronic pain or those who are not responsive to opioid analgesics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new methods for controlling pain, potentially reducing reliance on opioids and improving patient quality of life.
How similar studies have performed: Previous research has shown promise in using immune checkpoint inhibitors for various conditions, but this specific application for pain management is relatively novel.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JI, RU-RONG — DUKE UNIVERSITY
- Study coordinator: JI, RU-RONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.